Tabla de contenido
Publicidad
1. Lobatón T, López-García A, Rodríguez-Moran-
ta F, et al. A new rapid test for fecal calpro-
tectin predicts endoscopic remission and
postoperative recurrence in Crohn's disease.
J Crohns Colitis. 2013, 7(12):e641-51.
2. Lobatón Ortega T, Rodríguez-Moranta F, Lopez
A, et al. A new rapid quantitative test for fecal
calprotectin predicts endoscopic activity in
ulcerative colitis. Inflamm Bowel Dis. 2013,
19(5):1034-42.
3. Wright EK, Kamm MA, De Cruz P, et al., Mea-
surement of fecal calprotectin improves
monitoring and detection of recurrence of
Crohn's disease after surgery. Gastroenterolo-
gy. 2015, 148(5):938-947.
4. Naismith GD, Smith LA, Barry SJ et al. A pro-
spective evaluation of the predictive value of
faecal calprotectin in quiescent Crohn's disea-
se. J Crohns Colitis. 2014, 8(9):1022-9.
5. Ferreiro-Iglesias R, Barreiro-de Acosta M,
Lorenzo-Gonzalez A et al. Usefulness of a
rapid faecal calprotectin test to predict relap-
se in Crohn's disease patients on maintenan-
ce treatment with adalimumab. Scand J
Gastroenterol. 2015, 23:1-6.
6. Ferreiro-Iglesias R1, Barreiro-de Acosta M,
Otero Santiago M, Lorenzo Gonzalez A, Alonso
de la Peña C, Benitez Estevez AJ, Domin-
guez-Muñoz JE. Fecal calprotectin as Predic-
tor of Relapse in Patients With Inflammatory
Bowel Disease Under Maintenance Infliximab
Therapy.
J
Clin
50(2):147-51.
7. Guardiola J., Lobatón T, Rodríguez-Alonso L,
et al. Fecal Level of calprotectin Identifies
Histologic Inflammation in Patients with
Ulcerative Colitis In Clinical And Endoscopic
Remission. Clinical Gastroenterology and
Hepatology 2014, 12(11):1865-70.
LF-IBDOC8
BIBLIOGRAFÍA
Gastroenterol.
2015,
8. Lasson A, Öhman L, Stotzer PO et al. Pharma-
cological intervention based on fecal calpro-
tectin levels in patients with ulcerative colitis
at high risk of a relapse: A prospective, ran-
domized, controlled study. United European
Gastroenterol J. 2015 ;3(1):72-9.
9. Lin JF, Chen JM, Zuo JH et al. Meta-analysis:
fecal calprotectin for assessment of inflam-
matory bowel disease activity.
Bowel Dis. 2014 Aug;20(8):1407-15.
10. Bressler B, Panaccione R, Fedorak RN, et al.
Clinicians' guide to the use of fecal calprotec-
tin to identify and monitor disease activity in
inflammatory bowel disease. Can J Gastro-
enterol Hepatol. 2015, 29(7):369-72.
11. Peyrin-BL, Sandborn W, Sands BE et al. Selec-
ting Therapeutic Targets in Inflammatory
Bowel Disease (STRIDE): Determining Thera-
peutic Goals for Treat-to-Target. Am J Gastro-
enterol. 2015, 110:1324-38
12. Molander P, Färkkiläb M, Ristimäkic A, et al.
Does Fecal calprotectin Predict Short-Term
Relapse After Stopping Tnfalpha-Blocking
Agents In Inflammatory Bowel Disease Pati-
ents In Deep Remission? Journal of Crohn's
and Colitis, 2015, 33–40.
13. De Vos M, Dewit O, D'Haens G et al. Consecu-
tive fecal calprotectin measurements to pre-
dict relapse in patients with ulcerative colitis
receiving infliximab maintenance therapy.
Inflamm Bowel Dis. 2013, 9:2111-2117.
14. Fagerberg UL, Lööf L, Myrdal U et al. Colorectal
inflammation is well predicted by fecal cal-
protectin in children with gastrointestinal
symptoms. J Pediatr Gastroenterol Nutr.
2005, 40(4):450-5.
15. Kapel N, Campeotto F, Kalach N et al. Faecal
calprotectin in term and preterm neonates. J
Pediatr
Gastroenterol
51(5):542-7.
31/32
Fecha de revisión: 22-01-2019
Inflamm
Nutr.
2010
Publicidad
Tabla de contenido
